Consano Bio, a clinical-stage biotechnology company advancing novel therapeutics designed to address serious pain conditions, today announced that CEO Andrew Hall will present at the BIO Investment & Growth Summit, taking place March 2–3, 2026, in Miami, Florida.
During the presentation, Mr. Hall will provide an overview of Consano Bios’ development strategy and clinical progress for C-1101, its lead investigational therapy being evaluated as a potential treatment for chronic lumbosacral radiculopathy (chronic sciatica), a condition with significant unmet medical need and no FDA-approved pharmaceutical options.
Details of the presentation are as follows:
|
Event: |
BIO Investment & Growth Summit |
|
Date & Time: |
March 2, 2026 at 1:45 p.m., ET |
|
Location: |
ERC Ballroom 2C |
|
Presenter: |
Andrew Hall, Chief Executive Officer |
During the conference, members of Consano Bio’s management team will conduct one-on-one meetings with registered investors and potential partners.